Branford’s Tangen Biosciences has won a federal contract valued at up to $9.4 million to develop an Anthrax diagnostic test.

The contract from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) will advance the ability to combat the threat of Anthrax, a potentially deadly bacteria that can cause skin, lung and other diseases, by utilizing Tangen’s TangenDx Molecular Diagnostic System.